Clinical Trial

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

Study acronym: EDELWEISS
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-010 in subjects with hemophilia A. The study will have a dose-escalation design with elements of phase I/II seamless adaptive design.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-14.
Status change: Recruiting → Active, Not Recruiting 2025-04-22
Trial Details
NCT Number NCT06185335
Lead Sponsor Biocad
Conditions Hemophilia A
Enrollment 50 participants
Start Date 2023-07-26
Primary Completion 2025-12 (estimated)
Study Completion 2033-06 (estimated)
Updated on ClinicalTrials.gov 2025-04-24